Format

Send to

Choose Destination
Ann Rheum Dis. 2017 Sep;76(9):e32. doi: 10.1136/annrheumdis-2016-211045. Epub 2017 Feb 9.

Response to: 'Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease' by Orlando et al.

Author information

1
Department of Rheumatology, Ghent University Hospital, Ghent, Belgium.
2
VIB Inflammation Research Centre, Ghent University, Ghent, Belgium.

KEYWORDS:

Arthritis; Inflammation; Spondyloarthritis; Treatment

PMID:
28183720
DOI:
10.1136/annrheumdis-2016-211045
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center